This review explains how obesity causes resistance to both leptin (the fullness hormone) and ghrelin (the hunger hormone), disrupting the brain's ability to regulate energy balance.
Dual hormone resistanceObesity causes the brain to become resistant to both leptin (fullness) and ghrelin (hunger regulation) through distinct molecular pathways
What the researchers found
Leptin resistance and ghrelin resistance are both hallmarks of obesity and operate through distinct but interconnected cellular mechanisms. Leptin resistance involves impaired signaling through the JAK-STAT pathway in hypothalamic neurons, while ghrelin resistance involves disrupted cAMP signaling. Both forms of resistance contribute to a dysfunctional energy homeostasis system that perpetuates weight gain.
The review identifies several molecular targets within these resistance pathways that could potentially be exploited for pharmacological intervention in obesity treatment.
Why it matters
Understanding hormone resistance is central to solving the obesity epidemic. Many people assume weight gain is simply about willpower, but this review shows that obesity fundamentally alters the brain's hormonal communication system. By mapping the specific molecular breakdowns, researchers can identify precise targets for new anti-obesity drugs — potentially ones that restore hormone sensitivity rather than just mimicking or replacing these signals.
How the study worked
This is a narrative review article published in Nature Reviews Endocrinology. The authors synthesized findings from animal studies, cell biology experiments, and clinical observations to provide a comprehensive overview of leptin and ghrelin resistance mechanisms in obesity.
What this study cannot tell us
As a review article, this paper synthesizes existing research rather than presenting new experimental data. Much of the mechanistic evidence comes from animal models (particularly rodents), which may not fully reflect human physiology. The review was published in 2017, so more recent discoveries about hormone resistance pathways may not be included.
How to read the evidence
This is a review article in a top-tier journal (Nature Reviews Endocrinology), synthesizing evidence from multiple studies. While highly informative and authoritative, it does not present new primary data. It provides strong conceptual evidence but no direct clinical trial results.
When this study was published
Published in 2017, this review is well-established but nearly a decade old. The core mechanisms described remain valid, though newer research on GLP-1 drugs and incretin biology has since expanded the landscape of obesity pharmacology.
The bigger picture
This review connects directly to the GLP-1 drug revolution. While semaglutide and tirzepatide bypass leptin and ghrelin pathways entirely by targeting incretin receptors, understanding why the body's own appetite hormones fail in obesity helps explain why these newer drugs are so effective — and why restoring endogenous hormone sensitivity remains a parallel research frontier. It also raises questions about whether GLP-1 drugs might indirectly improve leptin or ghrelin sensitivity.
Questions still open
- Could drugs that restore leptin or ghrelin sensitivity be more effective long-term obesity treatments than hormone replacement approaches?
- Do GLP-1 receptor agonists like semaglutide partially restore leptin sensitivity as a secondary effect of weight loss?
- Are there genetic variants that make some individuals more susceptible to leptin or ghrelin resistance?
Common questions
What is leptin resistance and why does it matter?
How is ghrelin resistance different from leptin resistance?
Read the original research
The cellular and molecular bases of leptin and ghrelin resistance in obesity.
Nature reviews. Endocrinology, 13(6), 338-351
Citation
Cui, Huxing; López, Miguel; Rahmouni, Kamal. (2017). The cellular and molecular bases of leptin and ghrelin resistance in obesity.. Nature reviews. Endocrinology, 13(6), 338-351. https://doi.org/10.1038/nrendo.2016.222